HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis.

Abstract
Promoting angiogenesis is a key therapeutic target for protection from chronic ischemic cardiac injury. Endothelial-Monocyte-Activating-Polypeptide-II (EMAP II) protein, a tumor-derived cytokine having anti-angiogenic properties in cancer, is markedly elevated following myocardial ischemia. We examined whether neutralization of EMAP II induces angiogenesis and has beneficial effects on myocardial function and structure after chronic myocardial infarction (MI). EMAP II antibody (EMAP II AB), vehicle, or non-specific IgG (IgG) was injected ip at 30 min and 3, 6, and 9 days after permanent coronary artery occlusion in mice. EMAP II AB, compared with vehicle or non-specific antibody, significantly, p<0.05, improved the survival rate after MI, reduced scar size and attenuated the development of heart failure, i.e., left ventricular ejection fraction was significantly higher in EMAP II AB group, fibrosis was reduced by 24%, and importantly, more myocytes were alive in EMAP II AB group in the infarct area. In support of an angiogenic mechanism, capillary density (193/HPF vs. 172/HPF), doubling of the number of proliferating endothelial cells, and angiogenesis related biomarkers were upregulated in mice receiving EMAP II AB treatment as compared to IgG. Furthermore, EMAP II AB prevented EMAP II protein inhibition of in vitro tube formation in HUVECs. We conclude that blockade of EMAP II induces angiogenesis and improves cardiac function following chronic MI, resulting in reduced myocardial fibrosis and scar formation and increased capillary density and preserved viable myocytes in the infarct area.
AuthorsChujun Yuan, Lin Yan, Pallavi Solanki, Stephen F Vatner, Dorothy E Vatner, Margaret A Schwarz
JournalJournal of molecular and cellular cardiology (J Mol Cell Cardiol) Vol. 79 Pg. 224-31 (Feb 2015) ISSN: 1095-8584 [Electronic] England
PMID25456857 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies
  • Cytokines
  • Neoplasm Proteins
  • RNA-Binding Proteins
  • small inducible cytokine subfamily E, member 1
Topics
  • Animals
  • Antibodies (pharmacology)
  • Chronic Disease
  • Cytokines (antagonists & inhibitors, immunology)
  • Fibrosis
  • Heart (drug effects, physiopathology)
  • Human Umbilical Vein Endothelial Cells (drug effects, metabolism)
  • Humans
  • Male
  • Mice, Inbred C57BL
  • Myocardial Infarction (pathology, physiopathology, ultrasonography)
  • Myocytes, Cardiac (drug effects, metabolism, pathology)
  • Neoplasm Proteins (antagonists & inhibitors, immunology)
  • Neovascularization, Physiologic (drug effects)
  • RNA-Binding Proteins (antagonists & inhibitors, immunology)
  • Survival Analysis
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: